Jazz Pharmaceuticals PLC Equity-NMS: JAZZ

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$108.26
Open :$107.7
Today's high :$108.62
Today's low :$105.38
52W low :$95.49
52W high :$148.0568
EPS(TTM): :7.45
Shares O/S :61.63 M
Market cap :6.66 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Jazz Pharmaceuticals PLC $108.07 +0.52% 14.53 6.66B

Frequently Asked Questions

What is the share price of Jazz Pharmaceuticals PLC today?

Jazz Pharmaceuticals PLC (JAZZ) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.